Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer

Cancers
Claudio VernieriFilippo de Braud

Abstract

Background: Single-agent capecitabine (C) is a moderately effective chemotherapeutic compound in the treatment of patients with HER2-negative metastatic breast cancer (mBC). The capecitabine-vinorelbine (CV) combination is also used due to a good tolerability profile, but no studies have demonstrated its superiority over single-agent C. Methods: We conducted a retrospective analysis to compare overall response rate (ORR), progression-free survival (PFS), overall survival (OS) and incidence of adverse events (AEs) in patients with HER2-negative mBC treated with CV vs. single-agent C. Results: Out of 290 patients included in this study, 127 (43.8%) received single-agent C, while 163 (56.2%) patients were treated with CV. Median PFS was similar in patients treated with single-agent C or CV, while CV was associated with significantly longer OS in patients with hormone receptor-positive (HR+) BC. This OS advantage was confirmed at multivariable analysis also after propensity score-based matching of patients according to relevant clinical or tumor characteristics. When compared with single-agent C, CV was associated with higher incidence of G3/G4 and any-grade nausea/vomiting, diarrhea and increased transaminases. Conclusions: While ...Continue Reading

References

Feb 12, 1998·Annals of Internal Medicine·D B Rubin
Jun 23, 2000·British Journal of Cancer·R K Gregory, I E Smith
Jun 18, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joyce O'ShaughnessyRobert Leonard
Feb 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George W SledgeWilliam C Wood
May 2, 2003·Nature Reviews. Cancer·Daniel B LongleyPatrick G Johnston
Nov 25, 2004·The Oncologist·Chantal Bernard-MartyMartine J Piccart
Feb 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Emilio BajettaRoberto Buzzoni
Jun 9, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V LorussoUNKNOWN Gruppo Oncologico dell'Italia Meridionale
Apr 18, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lisa A CareyCharles M Perou
Mar 8, 2011·Lancet·Javier CortesUNKNOWN EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators
Jul 12, 2011·Cancer Treatment Reviews·Matti Aapro, Jindrich Finek
Dec 14, 2011·The New England Journal of Medicine·José BaselgaGabriel N Hortobagyi
Dec 19, 2013·The Cochrane Database of Systematic Reviews·Rachel F DearNicholas Wilcken
Jan 22, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter A KaufmanJavier Cortes
Feb 27, 2016·CA: a Cancer Journal for Clinicians·Giuseppe CuriglianoCarlo Maria Cipolla
Nov 3, 2016·The New England Journal of Medicine·Gabriel N HortobagyiJoyce O'Shaughnessy
Dec 14, 2016·The New England Journal of Medicine·Richard S FinnDennis J Slamon
Jan 7, 2017·Breast Cancer Research : BCR·Josee-Lyne EthierEitan Amir
Mar 12, 2017·Cancer Immunology, Immunotherapy : CII·Salman M ToorEyad Elkord
Jun 1, 2017·The New England Journal of Medicine·Norikazu MasudaMasakazu Toi
Oct 3, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew P GoetzAngelo Di Leo
Dec 5, 2017·Critical Reviews in Oncology/hematology·J CliffM Pirmohamed
Sep 23, 2018·Cancer Treatment Reviews·Javier CortesBruce A Littlefield
Oct 23, 2018·The New England Journal of Medicine·Peter SchmidUNKNOWN IMpassion130 Trial Investigators
Oct 27, 2018·Journal of Cellular Physiology·Elham SafarzadehBehzad Baradaran
May 16, 2019·The New England Journal of Medicine·Fabrice AndréUNKNOWN SOLAR-1 Study Group

❮ Previous
Next ❯

Methods Mentioned

BETA
ChT

Software Mentioned

R

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Related Papers

Obstetrics and Gynecology
J H Harger
Annales Françaises D'anesthèsie Et De Rèanimation
J L Pourriat
Proceedings of the National Academy of Sciences of the United States of America
Jochen Stritzker, Aladar A Szalay
© 2021 Meta ULC. All rights reserved